16252-63-4

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE is used as a chemical intermediate for the synthesis of pharmaceuticals, leveraging its potential biological activity and unique molecular structure to develop new drugs with therapeutic benefits.
Used in Agrochemical Industry:
3-AMINO-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE is used as a building block in the development of agrochemicals, such as pesticides and herbicides, due to its potential to enhance the effectiveness and selectivity of these compounds.
Used in Anti-inflammatory Applications:
3-AMINO-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE is studied for its potential anti-inflammatory properties, which may be utilized in the development of medications to alleviate inflammation and related symptoms in various conditions.
Used in Analgesic Applications:
3-AMINO-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE is being investigated for its potential analgesic properties, indicating its possible use in the development of pain-relieving medications to manage acute and chronic pain.
Further research is necessary to fully understand the applications and biological activities of 3-AMINO-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE, as its potential in various industries and therapeutic areas is still being explored.

InChI:InChI=1/C8H13N3O2/c9-11-6(12)8(10-7(11)13)4-2-1-3-5-8/h1-5,9H2,(H,10,13)

Upstream product

• 108-94-1 cyclohexanone 
• 702-62-5 spiro(imidazolidine-4,1'-cyclohexane)-2,5-dione 

Relevant academic research and scientific papers

Synthesis, characterization and antimicrobial activity of nalidixic acid derivatives with spirohydantoins

This article presents the synthesis of a series of amides, based on the interaction of several 3-aminospirohydantoins with nalidixic acid. The target compounds were characterized by physicochemical parameters, IR, 1H and 13C NMR spectral data. The antimicrobial activity of the products obtained was determined against Gram-positive bacteria Staphylococcus aureus and Bacillus subtilis, Gram-negative bacteria Escherichia coli, Pseudomonas aeruginosa and Salmonella abony, the yeasts Candida albicans and Saccharomyces cerevisiae and the molds Penicillium chrysogenum and Aspergillus niger. The relationship between structure and biological activity of the products obtained was discussed. It was found that the most effective compounds are tetralin (5f) and indane (5g) derivatives, which exhibit a pronounced antimicrobial activity against both tested Gram-positive and Gram-negative bacteria.

Synthesis, structure and cytotoxicity of platinum(IV) complexes of 3-aminocyclohexanespiro-5-hydantoin and 3-aminocycloheptanespiro-5-hydantoin

Two new platinum(IV) complexes of 3-aminocyclohexanespiro-5-hydantoin (achsh) and 3-aminocycloheptanespiro-5-hydantoin (achpsh) were prepared and characterized. Ab initio calculation of the structure and the measurements of IR and NMR spectra of complexes were also performed. The complexes were evaluated for in vitro cytotoxicity in murine erythroleukemia (MEL) cells, clone F4N. The complexes exerted low in vitro toxicity, comparable with that of the corresponding platinum(II) complexes.

Aminoderivatives of cycloalkanespirohydantoins: Synthesis and biological activity

3-Aminocycloalkanespiro-5-hydantoins were synthesized and their biological activity was studied. In contrast to hydantoins, these compounds failed to induce either anticonvulsive effects in the central nervous system or inhibitory effects on cholinergic contractions in the enteric nervous system. However, they exerted well pronounced, atropinsensitive, contractile effects on the guinea-pig ileum longitudinal muscle preparations. Structure-activity relationships established allow the assumption that: (i) the reduction of the ring size in the molecule of the spirohydantoins leads to an increase in the potency of the respective analogue to induce contractile effect; (ii) the introduction of -NH2 in position 3 increases the ability of all the compounds studied to exert contractions; (iii) the enlargement of the ring leads to: (1) an increase of the degree of desensitization of the preparations; and (2) a decrease (except 1a) of the potency of the analogues to exert contractile effects.